Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Microscopic visualization of metabotropic glutamate receptors on the surface of living cells using bifunctional magnetic resonance imaging probes.
ACS Chem. Neurosci. 5, 128-137 (2014)
A series of bimodal metabotropic glutamate-receptor targeted MRI contrast agents has been developed and evaluated, based on established competitive metabotropic Glu receptor subtype 5 (mGluR5) antagonists. In order to directly visualize mGluR5 binding of these agents on the surface of live astrocytes, variations in the core structure were made. A set of gadolinium conjugates containing either a cyanine dye or a fluorescein moiety was accordingly prepared, to allow visualization by optical microscopy in cellulo. In each case, surface receptor binding was compromised and cell internalization observed. Another approach, examining the location of a terbium analogue via sensitized emission, also exhibited nonspecific cell uptake in neuronal cell line models. Finally, biotin derivatives of two lead compounds were prepared, and the specificity of binding to the mGluR5 cell surface receptors was demonstrated with the aid of their fluorescently labeled avidin conjugates, using both total internal reflection fluorescence (TIRF) and confocal microscopy.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
3.871
0.972
10
16
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Imaging Agents ; Lanthanides ; Mglur5 ; Microscopy ; Mri
Sprache
englisch
Veröffentlichungsjahr
2014
Prepublished im Jahr
2013
HGF-Berichtsjahr
2013
e-ISSN
1948-7193
Zeitschrift
ACS Chemical Neuroscience
Quellenangaben
Band: 5,
Heft: 2,
Seiten: 128-137
Verlag
American Chemical Society (ACS)
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30505 - New Technologies for Biomedical Discoveries
30205 - Bioengineering and Digital Health
30502 - Diabetes: Pathophysiology, Prevention and Therapy
30205 - Bioengineering and Digital Health
30502 - Diabetes: Pathophysiology, Prevention and Therapy
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-552000-001
G-505590-001
G-552000-002
G-505590-001
G-552000-002
PubMed ID
24251400
Scopus ID
84894477652
Erfassungsdatum
2013-12-11